← Back to Search

Octreotide for Liver Resection

Phase 2
Waitlist Available
Led By Sanjay Reddy, MD
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial will study whether the use of octreotide can help improve liver regeneration after major liver resection surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rates of Liver Recovery Will be Determined by Area Under the Curve (AUC) for Total Bilirubin and INR for Each Group
Secondary outcome measures
Evaluate the Incidence of Post-hepatectomy Liver Failure, Bile Leak, Overall.
Rate of Hepatic Parenchymal Regeneration in Patients Treated With Octreotide Vs Placebo After Major Liver Hepatectomy.

Side effects data

From 2013 Phase 3 trial • 429 Patients • NCT00412061
53%
Diarrhoea
51%
Stomatitis
48%
Fatigue
43%
Nausea
43%
Oedema peripheral
41%
Rash
32%
Vomiting
30%
Abdominal pain
30%
Decreased appetite
30%
Headache
27%
Anaemia
27%
Weight decreased
27%
Cough
27%
Dyspnoea
24%
Asthenia
23%
Hypokalaemia
20%
Pyrexia
20%
Dysgeusia
20%
Pruritus
20%
Hyperglycaemia
18%
Arthralgia
16%
Thrombocytopenia
15%
Pain in extremity
15%
Back pain
15%
Epistaxis
14%
Constipation
13%
Dizziness
13%
Aphthous stomatitis
13%
Flatulence
13%
Upper respiratory tract infection
13%
Urinary tract infection
11%
Dry skin
11%
Hypertension
10%
Musculoskeletal pain
10%
Abdominal pain upper
10%
Dry mouth
9%
Oropharyngeal pain
9%
Pneumonitis
9%
Nasopharyngitis
9%
Insomnia
9%
Flushing
8%
Neutropenia
8%
Dehydration
8%
Ascites
8%
Haemorrhoids
8%
Mouth ulceration
8%
Muscle spasms
8%
Musculoskeletal chest pain
8%
Erythema
8%
Hypercholesterolaemia
8%
Hypocalcaemia
7%
Leukopenia
7%
Chills
7%
Hypomagnesaemia
7%
Myalgia
7%
Blood creatinine increased
7%
Dysphagia
7%
Anxiety
7%
Depression
7%
Hyperlipidaemia
6%
Pleural effusion
6%
Abdominal distension
6%
Alopecia
6%
Sinusitis
6%
Dysuria
5%
Hypophosphataemia
5%
Pollakiuria
5%
Aspartate aminotransferase increased
5%
Bronchitis
5%
Onychoclasis
4%
Alanine aminotransferase increased
4%
Hyperhidrosis
4%
Small intestinal obstruction
4%
Pneumonia
4%
Dyspnoea exertional
3%
Pulmonary embolism
3%
General physical health deterioration
2%
Ileus
2%
Renal failure
1%
Colitis
1%
Carcinoid heart disease
1%
Angina pectoris
1%
Small intestinal stenosis
1%
Atrial septal defect
1%
Hypoglycaemia
1%
Cholecystitis acute
1%
Gastroenteritis
1%
Bone pain
1%
Flank pain
1%
Subileus
1%
Cardiac failure
1%
Cardiac failure congestive
1%
Carcinoid syndrome
1%
Abdominal pain lower
1%
Rectal haemorrhage
1%
Malaise
1%
Non-cardiac chest pain
1%
Cachexia
1%
Hypoxia
1%
Interstitial lung disease
1%
Syncope
1%
Renal failure acute
1%
Intestinal obstruction
1%
Cellulitis
1%
Hepatic failure
1%
Sepsis
1%
Metabolic acidosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo + Octreotide
Everolimus + Octreotide
Everolimus Open Label

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Octreotide treatment armExperimental Treatment1 Intervention
Octreotide will be administered post-operatively until day 5
Group II: Placebo ArmPlacebo Group1 Intervention
Normal saline will be administered post-operatively until day 5
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Octreotide
2006
Completed Phase 4
~2360

Find a Location

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor
227 Previous Clinical Trials
37,486 Total Patients Enrolled
Sanjay Reddy, MDPrincipal InvestigatorFox Chase Cancer Center
1 Previous Clinical Trials
242 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
2017. "Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03179995.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top